Isoquercetin impaired tumor growth and vascularization, resulting in approximately 65% fewer blood vessels than untreated animals and 50% fewer than bevacizumab-treated animals.
Does isoquercetin reduce tumor growth and vascularization in a xenogeneic colon cancer mouse model?
Isoquercetin demonstrates antitumor and antiangiogenic activity in a colon cancer xenograft model by impairing vascularization and differentially modulating VASH1 and VASH2 expression.
Effect estimate: 65% reduction vs untreated
p-value: p=<0.05
// Daniel de Castilho da Silva 1 , * , Guilherme Di Camillo Orfali 2 , * , Maycon Giovani Santana 3 , Jessica Kaoru Yamamoto Palma 3 , Isabella Ramos de Oliveira Assunção 3 , Isadora Moraes Marchesi 2 , Ana Yoshie Kitagawa Grizotto 2 , Natália Peres Martinez 1 , Simone Felliti 4 , José Aires Pereira 5 and Denise Gonçalves Priolli 6 1 Programme Stricto Sensu in Health Science, Sao Francisco University Medical School, Sao Paulo, Brazil 2 Escola Paulista de Medicina, São Paulo, Brazil 3 Scientific Initiation Programme, Sao Francisco University Medical School, Sao Paulo, Brazil 4 Department of Oncology, Sao Francisco University Medical School, Sao Paulo, Brazil 5 Department of Pathology, Sao Francisco University Medical School, Sao Paulo, Brazil 6 Postgraduate Programme Stricto Sensu in Health Science, Sao Francisco University Medical School, Sao Paulo, Brazil * These authors contributed equally to this work Correspondence to: Denise Gonçalves Priolli, email: depriolli@gmail.com Keywords: target; angiogenic proteins; neoplasms; flavonols; antitumor assays-xenograft model Received: September 24, 2021 Accepted: December 08, 2021 Published: February 08, 2022 Copyright: © 2022 da Silva et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Tumor cells trigger angiogenesis through the expression of angiogenic factors. Vasohibins (VASHs) are a family of peptides that regulate angiogenesis. Flavonoids have antiproliferative antitumor properties; however, few studies have highlighted their antiangiogenic potential. This study evaluated the flavonoid isoquercetin (Q3G) as an antitumor compound related to colon cancer vascularization and regulation of VASH1 and 2. Mice bearing xenogeneic colon cancer ( n = 15) were divided into 3 groups: Q3G-treated (gavage, daily over a week), bevacizumab-treated (intraperitoneal, single dose), or untreated animals. Tumor growth, histological characteristics, blood vessel volume, and VASH1 and 2 expressions were analyzed. Q3G impaired tumor growth and vascularization, upregulated VASH1, and downregulated VASH2 in comparison to untreated animals. Mice treated with Q3G showed approximately 65% fewer blood vessels than untreated animals and 50% fewer blood vessels than mice treated with bevacizumab. Thus, we show that Q3G has antitumor activity, impairs vascularization, and differentially modulates VASH1 and 2 expressions in colon cancer.
Silva et al. (Tue,) conducted a other in Xenogeneic colon cancer (n=15). Isoquercetin (Q3G) vs. Untreated (vehicle) and Bevacizumab was evaluated on Blood vessel content (65% reduction vs untreated, p=<0.05). Isoquercetin impaired tumor growth and vascularization, resulting in approximately 65% fewer blood vessels than untreated animals and 50% fewer than bevacizumab-treated animals.